Cevian Capital disclosed a stake above 14% in Smith & Nephew in late July, marking the Swedish activist's largest European healthcare position since its ConvaTec engagement and its second London-listed medtech campaign in eighteen months. The filing confirms $2.4 billion of exposure at current pricing, cementing Cevian as the second-largest institutional holder behind only BlackRock.
The disclosure followed a quiet accumulation period through the second quarter, during which Smith & Nephew shares traded in a narrow £9.80–£10.60 band. Cevian crossed 10% in March without public comment, then added another 400 basis points before the July threshold triggered mandatory disclosure under UK Listing Rules. The firm has not yet released a public letter or nominated board candidates, but the position size alone places it firmly in operational influence territory. Smith & Nephew's market capitalization sits near £8.7 billion ($11.2 billion), down 18% from its 2021 peak despite incremental margin improvement in orthopedics and wound management.
Cevian's entry extends a sustained activist focus on European medical device conglomerates trading below sum-of-parts valuations. The firm pushed ConvaTec to restructure its ostomy and infusion divisions in 2020, then exited at a 34% gain eighteen months later. Smith & Nephew's segmented portfolio—orthopedics, sports medicine, and advanced wound care—presents similar carve-out optionality, particularly as private equity groups have paid 14–16x EBITDA for standalone wound-care platforms over the past two years. The company's 15.8% operating margin trails Stryker's 19.2% and Zimmer Biomet's 17.4%, leaving structural improvement upside if Cevian presses for portfolio rationalization or separation of the lower-margin wound business.
Allocators should watch for a formal engagement letter in the next 30–45 days, likely timed to Smith & Nephew's interim results in early August. Cevian typically requests board representation once it crosses 12%, and the firm's portfolio concentration—just eight public positions globally—signals willingness to sustain multi-year campaigns. Secondary follow-on stakes from other activists have appeared in 60% of Cevian's prior disclosures within 90 days, creating potential for a consortia dynamic if the company resists operational changes. Private equity interest in the wound-care segment has intensified since PAI Partners acquired Medline's European operations in March for $3.2 billion, establishing a recent precedent for carve-out valuations.
The position confirms Cevian's pivot toward healthcare industrials after exiting its Pearson and Atos stakes in late 2023, concentrating capital in sectors with visible cost structures and defensible IP moats.